Related Experiment Video

Updated: Jan 20, 2026

MicroRNA-based Regulation of Picornavirus Tropism
09:05

MicroRNA-based Regulation of Picornavirus Tropism

Published on: February 6, 2017

8.0K

Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses

Autumn J Schulze1

  • 1Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. schulze.autumn@mayo.edu.

Methods in Molecular Biology (Clifton, N.J.)
|September 6, 2019
PubMed

Insights

Developing potent oncolytic virus monotherapies requires enhanced targeting. MicroRNA-detargeting improves safety and efficacy by preventing off-target toxicities, offering a promising strategy for cancer treatment.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Oncolytic viruses show safety but suboptimal monotherapy efficacy.
  • Combination therapies are promising, yet potent monotherapies are needed.
  • Improved virus targeting is crucial to minimize off-target toxicities.

Purpose of the Study:

  • To present methods for assessing microRNA-detargeting in oncolytic viruses.
  • To evaluate the genetic stability and detargeting efficiency of engineered viruses.
  • To determine the therapeutic index of microRNA-detargeted picornaviruses.

Main Methods:

  • In vitro testing of microRNA response element genetic stability.
  • In vivo evaluation of detargeting efficiency and therapeutic index.
  • Adaptation of microRNA-detargeting strategies for various oncolytic virus classes.

Main Results:

  • Established methods to test microRNA response element stability.
  • Demonstrated detargeting efficiency and improved therapeutic index in vivo.
  • Validated microRNA-detargeting as a tool for oncolytic picornaviruses.

Conclusions:

  • MicroRNA-detargeting enhances the safety and efficacy of oncolytic viruses.
  • The described assays are crucial for developing safer oncolytic virus therapies.
  • This approach is adaptable to different oncolytic virus families for broader application.
Keywords:
Genetic stabilityMicroRNAOncolytic picornavirusTargetingVirotherapy

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.1K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Related Concept Videos

MicroRNA-based Regulation of Picornavirus Tropism09:05

MicroRNA-based Regulation of Picornavirus Tropism

We describe here a method for regulating picornavirus tropism by incorporating sequences complementary to specific microRNAs into the viral genome. This protocol can be adapted to all different classes of viruses with modifications based upon the length and nature of their life cycle.
8.0K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Oncolytic viruses are promising for cancer therapeutics. The ability to ascertain the infectability of live tissue specimens obtained from patients prior to treatment is a unique advantage of this therapeutic approach. This protocol describes how to process tissues for ex vivo infection with oncolytic virus and subsequent viral...
13.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.0K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

This protocol describes xenograft and orthotopic mouse models of human thyroid tumorigenesis as a platform to test microRNA-based inhibitor treatments. This approach is ideal to study the function of non-coding RNAs and their potential as new therapeutic...
7.8K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Tissue-specific microRNA inhibition is a technology that is underdeveloped in the microRNA field. Herein, we describe a protocol to successfully inhibit the miR-181 microRNA family in myoblast cells from the heart. Nanovector technology is used to deliver a microRNA sponge that demonstrates significant in vivo cardio-specific miR-181 family...
7.9K
Simultaneous ex vivo Functional Testing of Two Retinas by in vivo Electroretinogram System09:16

Simultaneous ex vivo Functional Testing of Two Retinas by in vivo Electroretinogram System

Ex vivo ERG can be used to record electrical activity of retinal cells directly from isolated intact retinas of animals or humans. We demonstrate here how common in vivo ERG systems can be adapted for ex vivo ERG recordings in order to dissect the electrical activity of retinal...
9.8K